LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "bemcentinib" as a keyword



Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib—a case report

Sign Up to like & get
recommendations! Published in 2020 at "Oral and Maxillofacial Surgery"

DOI: 10.1007/s10006-020-00851-w

Abstract: Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to… read more here.

Keywords: bemcentinib; necrotizing periodontitis; osteonecrosis jaw; medication related ... See more keywords

Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial

Sign Up to like & get
recommendations! Published in 2025 at "Nature Communications"

DOI: 10.1038/s41467-025-58179-6

Abstract: Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib is an orally bioavailable, potent, highly selective inhibitor of AXL, a receptor tyrosine kinase associated… read more here.

Keywords: low dose; combination; acute myeloid; bemcentinib ... See more keywords
Photo by regdoesstuff from unsplash

Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-3245

Abstract: STK11 (LKB1) is a tumor suppressor, and loss-of-function mutations contribute to tumorigenesis. Mutations in the STK11 gene (STK11m) are present in ~ 20% of NSCLCs and are associated with poor response to chemotherapy and immune… read more here.

Keywords: bemcentinib; stk11; tumor; axl ... See more keywords

First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.7043

Abstract: 7043 Background: The RTK AXL represents a therapeutic target promoting AML cell proliferation and survival by pleiotropic mechanisms and is a negative regulator of anti-tumour immunity. Bemcentinib is a first-in-class, highly selective, oral AXL inhibitor… read more here.

Keywords: bemcentinib; axl; combination; aml ... See more keywords